Loading
A phase 1/2 trial of FOLFOX, FLOT, CAPOX in colorectal cancer and pancreatic ductal adenocarcinoma, run by Crossignal Therapeutics, Inc., now recruiting.
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06598007 by Crossignal Therapeutics, Inc., with 78 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-06-20. Interventions recorded: CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin). Conditions listed: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.